Loading search results
Unable to achieve recruitment
CADAS
Observational Cohort Study of Changes in Carotid Plaque Volume After Stroke.
Sponsor study identifier
observational
0
1 country
3
Study Start
November 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
September 9, 2021
Actual (reported)Study Completion
September 9, 2021
Actual (reported)Stroke is a significant medical problem with 150,000 events occurring per year in the UK and incurring healthcare costs of £4 billion per year. Fifty percent of strokes will leave a lasting disability on first manifestation and 10-15% (roughly 16,500 per year) are unheralded ischaemic events in previously asymptomatic Carotid artery disease. Carotid Artery Disease is caused by the formation of an atherosclerotic plaque in the vessel. Stroke or TIA occurs when plaque or adherent thrombus breaks off and embolises to the brain, blocking off its blood supply. Hence, a carotid plaque is said to be symptomatic if it has caused a Stroke or TIA in the territory of the brain supplied by that vessel in the previous six months. Currently, the degree of stenosis (narrowing) of the artery by doppler ultrasound is the main assessment performed. Doppler ultrasound measures stenosis and elevation of blood flow velocity in the artery prior to surgical intervention. However, it has been shown that the degree of stenosis is a poor predictor of stroke as many asymptomatic patients have severe stenosis and many symptomatic patients have moderate stenosis. Stenosis is a two dimensional assessment of a 3-D structure. Other features of the plaque should be considered including the volume of the carotid plaque and its constituents. Carotid Plaque Volume has been measured in 339 individuals, with plaque volume being higher in symptomatic than asymptomatic individuals. In this study, plaque volume did not correlate with stenosis degree. No studies have been conducted measuring the change in carotid plaque volume and morphology following a stroke. This pilot study will perform serial duplex scans on recently symptomatic individuals over a 12 week period and observe the changes in Plaque Volume and morphology. This will attempt to prove that carotid plaque volume is a better predictor of stroke than stenosis. The investigators will also aim to identify other plaque features that may have an important role in predicting stroke risk. Documenting the timescale of change in plaque volume will aid us in defining appropriate timescales for treating the symptomatic population and when those having medical management's risk has returned to baseline. Observing the change in plaque immediately after stroke will improve our knowledge of the changes in plaques that lead to symptoms and may in the future help us predict which patients with asymptomatic carotid stenosis need operation.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 9, 2021
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 25, 2018
Actual (reported)October 26, 2018
Actual (reported)November 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 9, 2021
Actual (reported)September 9, 2021
Actual (reported)Changes in Carotid Plaque Volume using 3-D tomographic Ultrasound over time following acute cerebral event.
Measured by 3-D tUS with contrast administration
Measured at 5 separate timepoints up to 12 weeks following acute cerebral event.
Identify adverse morphological features within the carotid plaque by 3-D tomographic Ultrasound.
At five timepoints over 12 weeks.
Assess the acute inflammatory response to stroke on platelet aggregation and resistance to antiplatelet agents.
Twice during study period
3-D tUS at five timepoints following acute ipsilateral stroke or Transient Ischaemic attack (TIA) to document carotid plaque volume and presence or absence of adverse plaque features.
Blood test to test for platelet resistance to aspirin or clopidogrel and to measure effect of acute inflammatory response post event.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with recent stroke, with carotid artery disease not being considered for surgery.
Manchester University hospitals NHS Foundation Trust
Manchester, Greater Manchester, M23 9LT, United Kingdom
Northern Care Alliance, Salford Royal NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom
Manchester Foundation Trust, Wythenshawe site.
Manchester, United Kingdom
Charles McCollum, Prof.
University of Manchester
0 participants (actual enrollment reported by the registry).
First Submitted
October 25, 2018
First Posted
October 26, 2018
Study Start
November 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Contact the study team to confirm eligibility.
Primary Completion
September 9, 2021
Actual (reported)Study Completion
September 9, 2021
Actual (reported)Last Updated
September 27, 2021
Record last verified: 2021-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: